Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Coeptis Therapeutics Holdings Inc COEPW


Primary Symbol: COEP

Healthcare Biotechnology
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health S...


NDAQ:COEP - Post by User

Coeptis Therapeutics Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
  • MasterJediJazz2X
Post by MasterJediJazz2on Feb 07, 2025 10:00am
29 Views
Post# 36442548

$COEP This additional financing enables Coeptis greatly!

$COEP This additional financing enables Coeptis greatly!$COEP "This additional financing enables Coeptis to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI," added Dave Mehalick, President and CEO of COEPTIS.  https://quantisnow.com/insight/coeptis-completes-10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-5874744

User image

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities